Cel-Sci (NYSEAMERICAN:CVM) Issues Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) posted its quarterly earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, FiscalAI reports.

Cel-Sci Trading Down 2.4%

Shares of NYSEAMERICAN:CVM opened at $4.78 on Wednesday. The company has a current ratio of 2.26, a quick ratio of 2.20 and a debt-to-equity ratio of 0.36. Cel-Sci has a 12-month low of $1.98 and a 12-month high of $20.41. The business has a 50 day moving average of $5.40 and a two-hundred day moving average of $7.49. The company has a market capitalization of $40.20 million, a PE ratio of -0.49 and a beta of 0.77.

Institutional Trading of Cel-Sci

A number of hedge funds have recently added to or reduced their stakes in CVM. State Street Corp increased its holdings in Cel-Sci by 9.9% in the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after buying an additional 2,300 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Cel-Sci in the 4th quarter valued at about $83,000. HRT Financial LP acquired a new position in Cel-Sci in the 4th quarter worth about $60,000. Renaissance Technologies LLC purchased a new position in Cel-Sci during the fourth quarter worth approximately $81,000. Finally, Geode Capital Management LLC grew its holdings in Cel-Sci by 30.3% in the fourth quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock valued at $417,000 after purchasing an additional 18,432 shares during the period. 12.08% of the stock is owned by hedge funds and other institutional investors.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.